Does TRACON Pharmaceuticals Inc (TCON) Have Any Gas After Today’s Significant Increase?

September 17, 2017 - By Marie Mckinney

The stock of TRACON Pharmaceuticals Inc (NASDAQ:TCON) is a huge mover today! The stock increased 5.63% or $0.2 on September 15, reaching $3.75. About 190,448 shares traded. TRACON Pharmaceuticals Inc (NASDAQ:TCON) has declined 52.06% since September 17, 2016 and is downtrending. It has underperformed by 68.76% the S&P500.
The move comes after 9 months positive chart setup for the $62.46M company. It was reported on Sep, 17 by Barchart.com. We have $4.01 PT which if reached, will make NASDAQ:TCON worth $4.37M more.

Investors wait TRACON Pharmaceuticals Inc (NASDAQ:TCON) to report on November, 14. its quarterly earnings Wall Street analysts expect $-0.25 EPS, up $0.23 or 47.92 % from last year’s $-0.48 same quarter earnings. TRACON Pharmaceuticals Inc’s Wall Street analysts see -37.50 % EPS growth, taking into account the $-0.40 EPS reproted in the previous quarter,

TRACON Pharmaceuticals Inc (NASDAQ:TCON) Ratings Coverage

Among 4 analysts covering Tracon Pharmaceuticals Inc (NASDAQ:TCON), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Tracon Pharmaceuticals Inc had 4 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of TRACON Pharmaceuticals Inc (NASDAQ:TCON) has “Buy” rating given on Wednesday, December 21 by Jefferies. The stock has “Buy” rating by TH Capital on Wednesday, July 29. The stock has “Hold” rating by Zacks on Friday, September 4. The rating was initiated by Roth Capital with “Buy” on Wednesday, July 29.

More notable recent TRACON Pharmaceuticals Inc (NASDAQ:TCON) news were published by: Globenewswire.com which released: “TRACON Pharmaceuticals Announces Closing of Public Offering and Full Exercise …” on November 29, 2016, also Globenewswire.com with their article: “TRACON Pharmaceuticals to Present at the 29th Annual Roth Conference” published on March 06, 2017, Seekingalpha.com published: “Tracon Pharmaceuticals: An Underdog Can Rise Up” on February 21, 2017. More interesting news about TRACON Pharmaceuticals Inc (NASDAQ:TCON) were released by: Seekingalpha.com and their article: “TRACON Pharmaceuticals’ (TCON) CEO Charles Theuer on Q1 2017 Results …” published on May 12, 2017 as well as Globenewswire.com‘s news article titled: “TRACON Pharmaceuticals Reports Second Quarter Financial Results and Provides …” with publication date: August 08, 2017.

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $62.46 million. The Firm is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases. It currently has negative earnings. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.